ANCA-Associated Vasculitis: Diagnosis and Approach to Therapy
Einstein/Montefiore Department of Medicine Grand Rounds
Thursday, May 15, 2014
8:00 AM: Forchheimer Medical Science Building 3rd Floor Lecture Hall
Speaker & Info
Robert Spiera, MD
Professor of Clinical Medicine
Weill Cornell Medical College
Director, Scleroderma, Vasculitis, & Myositis Center
Department of Medicine/Division of Rheumatology
The Hospital for Special Surgery
Repeated at 12:15 pm, Cherkasky Auditorium, Montefiore Medical
Dr. Robert Spiera completed his medical education at the Yale University School of Medicine, his internal medicine residency at the New York Hospital/Weill Cornell Medical Center, and his rheumatology fellowship at the Hospital for Special Surgery in New York City. He is presently a Professor of Clinical Medicine at the Weill Cornell Medical College of Cornell University, and the Director of the Scleroderma, Vasculitis, and Myositis Center at the Hospital for Special Surgery.
Dr. Spiera has had a longstanding interest in scleroderma and vasculitis, and has a large clinical experience in the treatment of those disorders. He has also been involved in clinical and translational investigation in those areas. His particular areas of investigation in vasculitis have included the ANCA associated vasculitidies, including a central role in the RAVE trial, which established Rituximab as an effective therapy in ANCA associated vasculitis.
He has also been a lead investigator in investigator initiated clinical trials in polymyalgia rheumatica and systemic sclerosis. He has been an author on over fifty peer-reviewed articles, many of which relate to the treatment of vasculitis, and has authored numerous chapters in textbooks, including those in Cecil's Textbook of Medicine on Giant Cell Arteritis.
Dr. Spiera is the recipient of the Scleroderma Foundation Founder's award for clinical investigation in scleroderma. He serves on the Medical Advisory Board of the National Scleroderma Foundation, and the Scientific Advisory Board and Medical Advisory Board of the Vasculitis Foundation.
Objectives - After attending this activity, participants will be able to:
- Understand the clinical spectrum of ANCA associated vasculitic syndromes and the use of ANCA in the diagnosis and management of these disorders
- Understand the distinction between "severe" and "limited" disease, and how that distinction affects our approach to therapy
- Recognize the distinction between remission "induction" and remission "maintenance" in the treatment of ANCA associated vasculitis
- Understand evolving concepts in the approach to treatment of these disorders, including the emerging use of newer therapies in the treatment of these disorders
Accreditation: Albert Einstein College of Medicine designates this
educational activity for a maximum of 1 credit towards the AMA Physician's
Recognition Award. Each physician should claim only those credits that
he/she actually spent in the educational activity.
Division of Rheumatology (Department of Medicine)